231 related articles for article (PubMed ID: 9156694)
1. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations.
Fuhr U; Rost KL; Engelhardt R; Sachs M; Liermann D; Belloc C; Beaune P; Janezic S; Grant D; Meyer UA; Staib AH
Pharmacogenetics; 1996 Apr; 6(2):159-76. PubMed ID: 9156694
[TBL] [Abstract][Full Text] [Related]
2. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva.
Fuhr U; Rost KL
Pharmacogenetics; 1994 Jun; 4(3):109-16. PubMed ID: 7920690
[TBL] [Abstract][Full Text] [Related]
3. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites.
Butler MA; Lang NP; Young JF; Caporaso NE; Vineis P; Hayes RB; Teitel CH; Massengill JP; Lawsen MF; Kadlubar FF
Pharmacogenetics; 1992 Jun; 2(3):116-27. PubMed ID: 1306111
[TBL] [Abstract][Full Text] [Related]
4. Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans.
Rasmussen BB; Brøsen K
Br J Clin Pharmacol; 1997 Mar; 43(3):253-8. PubMed ID: 9088579
[TBL] [Abstract][Full Text] [Related]
5. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment.
Rostami-Hodjegan A; Nurminen S; Jackson PR; Tucker GT
Pharmacogenetics; 1996 Apr; 6(2):121-49. PubMed ID: 9156692
[TBL] [Abstract][Full Text] [Related]
6. Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities.
Fuchs P; Haefeli WE; Ledermann HR; Wenk M
Eur J Clin Pharmacol; 1999 Jan; 54(11):869-76. PubMed ID: 10027663
[TBL] [Abstract][Full Text] [Related]
7. Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities.
Hakooz NM
Curr Drug Metab; 2009 May; 10(4):329-38. PubMed ID: 19519341
[TBL] [Abstract][Full Text] [Related]
8. NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios.
Nyéki A; Buclin T; Biollaz J; Decosterd LA
Br J Clin Pharmacol; 2003 Jan; 55(1):62-7. PubMed ID: 12534641
[TBL] [Abstract][Full Text] [Related]
9. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping.
Kashuba AD; Bertino JS; Kearns GL; Leeder JS; James AW; Gotschall R; Nafziger AN
Clin Pharmacol Ther; 1998 May; 63(5):540-51. PubMed ID: 9630827
[TBL] [Abstract][Full Text] [Related]
10. Analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities.
McQuilkin SH; Nierenberg DW; Bresnick E
Cancer Epidemiol Biomarkers Prev; 1995 Mar; 4(2):139-46. PubMed ID: 7742721
[TBL] [Abstract][Full Text] [Related]
11. Relative Contributions of CYP1A2 and CYP2E1 to the Bioactivation and Clearance of 4-Aminobiphenyl in Adult Mice.
Wang S; Bott D; Tung A; Sugamori KS; Grant DM
Drug Metab Dispos; 2015 Jul; 43(7):916-21. PubMed ID: 25922528
[TBL] [Abstract][Full Text] [Related]
12. Salivary caffeine metabolic ratio in alcohol-dependent subjects.
Kukongviriyapan V; Senggunprai L; Prawan A; Gaysornsiri D; Kukongviriyapan U; Aiemsa-Ard J
Eur J Clin Pharmacol; 2004 Apr; 60(2):103-7. PubMed ID: 15022032
[TBL] [Abstract][Full Text] [Related]
13. Paraxanthine/Caffeine Concentration Ratios in Hair: An Alternative for Plasma-Based Phenotyping of Cytochrome P450 1A2?
De Kesel PM; Lambert WE; Stove CP
Clin Pharmacokinet; 2015 Jul; 54(7):771-81. PubMed ID: 25603821
[TBL] [Abstract][Full Text] [Related]
14. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.
Frye RF; Branch RA
Br J Clin Pharmacol; 2002 Feb; 53(2):155-62. PubMed ID: 11851639
[TBL] [Abstract][Full Text] [Related]
15. Why dried blood spots are an ideal tool for CYP1A2 phenotyping.
De Kesel PM; Lambert WE; Stove CP
Clin Pharmacokinet; 2014 Aug; 53(8):763-71. PubMed ID: 24980692
[TBL] [Abstract][Full Text] [Related]
16. Interaction of ibuprofen and probenecid with drug metabolizing enzyme phenotyping procedures using caffeine as the probe drug.
Vrtic F; Haefeli WE; Drewe J; Krähenbühl S; Wenk M
Br J Clin Pharmacol; 2003 Feb; 55(2):191-8. PubMed ID: 12580991
[TBL] [Abstract][Full Text] [Related]
17. Assessment of CYP1A2 activity in clinical practice: why, how, and when?
Faber MS; Jetter A; Fuhr U
Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):125-34. PubMed ID: 16128905
[TBL] [Abstract][Full Text] [Related]
18. [Effect of Tibetan medicine zuotai on the activity, protein and mRNA expression of CYP1A2 and NAT2].
Li XY; Liu YN; Li YP; Zhu JB; Yao XC; Li YF; Yang M; Yuan M; Fan XR; Yin YM
Yao Xue Xue Bao; 2014 Feb; 49(2):267-72. PubMed ID: 24761621
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics.
Perera V; Gross AS; Xu H; McLachlan AJ
J Pharm Pharmacol; 2011 Sep; 63(9):1161-8. PubMed ID: 21827488
[TBL] [Abstract][Full Text] [Related]
20. Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers.
Shirley KL; Hon YY; Penzak SR; Lam YW; Spratlin V; Jann MW
Neuropsychopharmacology; 2003 May; 28(5):961-6. PubMed ID: 12644842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
